house · trading 2023-02-06 → 2023-02-06
*Notional-weighted price return on disclosed buys from the last ~3 years, marked to the latest close — open positions, per-share (share counts aren't disclosed, so this is price performance, not realized $ P&L).
| Date | Ticker | Type | Amount | Est. price | Latest close | Return |
|---|---|---|---|---|---|---|
| 2023-02-06 | GSK | SELL | $1K–$15K | $35.34 | $50.45 2026-08-13 | -42.8% exit |
| 2023-02-06 | F | BUY | $1K–$15K | $13.14 | $13.89 2026-08-13 | +5.7% |
| 2023-02-06 | CCL | SELL | $1K–$15K | $11.87 | $28.42 2026-08-13 | -139.4% exit |
| 2023-02-06 | AMZN | SELL | $1K–$15K | $102.18 | $265.13 2026-08-13 | -159.5% exit |
Return: buys are marked to the latest close (open); sells tagged rt are realized round-trips vs a prior disclosed buy; exit = timing (how the stock moved after the sale, seller's perspective).
| Member | Shared tickers |
|---|---|
| James B. Renacci | 3 · AMZN, CCL, GSK |
| Josh Gottheimer | 3 · AMZN, CCL, F |
| Thomas H Tuberville | 3 · CCL, F, GSK |
| K. Michael Conaway | 3 · AMZN, F, GSK |
| Alan Armstrong | 3 · AMZN, CCL, F |
| David P. Roe | 3 · AMZN, F, GSK |
| Kenny Marchant | 3 · AMZN, F, GSK |
| Mike Kelly | 3 · AMZN, F, GSK |
| Marie Newman | 3 · AMZN, CCL, F |
| E. Scott Rigell | 3 · CCL, F, GSK |
| Thomas R Carper | 2 · F, GSK |
| Sheldon Whitehouse | 2 · AMZN, F |